PARP Inhibitors Market is projected to be valued at US$ 8.4 Billion by 2026

[179 Pages Report] Rising burden of various types of cancers such as ovarian, breast, prostate, and pancreatic cancer is anticipated to generate significant demand for PARP inhibitors. According to the Global Cancer Observatory (GLOBOCAN), countries such as China, the U.S., India, and Japan, collectively diagnose over 120,000 new cases of ovarian cancer each year.

The incidence of breast cancer is much higher in these countries, and with superior efficacy of PARP inhibitors as compared to other available cancer treatment options, the PARP inhibitors market is expected to gain significant revenue over the forecast period.

The global PARP inhibitors market is estimated to be valued at US$ 8.4 Bn by 2026, expanding at a significant CAGR from 2022 to 2026.

“The unique ability of PARP inhibitors to improve progression-free survival in ovarian and breast cancer patients is expected to generate extensive traction for the market, thereby propelling the growth of the global PARP inhibitors market over the forecast period.”

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-3197

Key Takeaways of PARP Inhibitors Market Study

  • Olaparib, with various expanded approvals for the treatment of ovarian cancer, breast cancer, and pancreatic cancer, and rapid increase in potential patient pool, contributed to the dominance of the segment by drug in 2021, and will continue to do so during the forecast period.
  • PARP inhibitors are regarded as a new standard of care for ovarian cancer after first-line platinum chemotherapy. Adoption of PARP inhibitors for ovarian cancer treatment has surged, and the trend is expected to continue during the forecast period, owing to the ability of PARP inhibitors to induce ovarian cancer patients into remission for longer periods of time as compared to any other marketed therapy.
  • With a strong pipeline, significant number of PARP inhibitors are expected to go for approval through the new drug application (NDA) process and for expanded approval to treat various types of cancers.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-3197

Strategic Acquisitions & Collaborations by Key Players to Widen Regional PresenceAll marketed PARP inhibitors are under patent, and with no generic launch in sight till 2027, the market is expected to remain consolidated till the second half of this decade. Key players in the PARP inhibitors market are undergoing major collaborative efforts, mergers, and acquisitions in order to expand their regional product offerings.

For example, in January 2022, GlaxoSmithKline plc acquired TESARO Inc., an oncology-focused biopharmaceutical company with a marketed PARP inhibitor named Zejula (Niraparib).

More Valuable Insights on PARP Inhibitors Market

Future Market Insights brings a comprehensive research report on forecast revenue growth at global, regional, and country levels, and provides an analysis of the latest industry trends in each of the segments from 2015 to 2026. The global PARP inhibitors market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

The study provide compelling insights on PARP inhibitors market on basis of drug (Olaparib, Niraparib, Rucaparib, and Talazoparib), indication (ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer), and distribution channel (retail pharmacies, hospital pharmacies, and online pharmacies), across seven major regions.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-3197

PARP Inhibitors Market by Category ByDrug Type: 

  • Olaparib
  • Niraparib
  • Rucaparib
  • Talazoparib

By Indication:

  • Ovarian Cancer
  • Breast Cancer
  • Prostate Cancer
  • Pancreatic Cancer

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Europe
  • Latin America
  • South Asia
  • East Asia
  • Oceania
  • Middle East And Africa

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

About the Author

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these